Great progress has been made in the development of new drugs to treat cancer and other serious illness. However, these therapies are often administered at suboptimal doses because of their effects on healthy tissue. The value of these therapies is further diminished because of the inability to predict in advance if a patient will respond to a particular therapy. Endocyte is addressing both of these issues using our small molecule drug conjugates (SMDC) technology and companion imaging diagnostics.
Small Molecule Drug Conjugates
Endocyte’s novel small molecule drug conjugates technology is designed to improve the specificity, safety, and efficacy of highly active drugs by targeting them directly to diseased cells. Our technology can be used to deliver a variety of drug therapies, from small molecule cancer drugs to larger proteins and RNA-based therapies.
Endocyte is also developing powerful companion diagnostic agents (such as etarfolatide (EC20) and EC0652) that are designed to predict in advance if a patient will respond to our drug therapy. By replacing the drug payload in our SMDC with an imaging agent, we can generate a patient-specific targeting profile to help identify likely responders.
Strong Clinical Stage Pipeline
Today, Endocyte has six targeted cancer drugs in clinical trials. We believe our patented technology may also have applications in developing better drugs to treat diseases such as rheumatoid arthritis, osteoarthritis, and atherosclerosis. This proprietary technology is being used today by a number of drug companies in collaboration with Endocyte.